vs

Side-by-side financial comparison of Epsilon Energy Ltd. (EPSN) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $14.8M, roughly 1.3× Epsilon Energy Ltd.). Epsilon Energy Ltd. runs the higher net margin — -83.9% vs -177.4%, a 93.5% gap on every dollar of revenue. On growth, Epsilon Energy Ltd. posted the faster year-over-year revenue change (65.7% vs -11.5%). Over the past eight quarters, Epsilon Energy Ltd.'s revenue compounded faster (36.2% CAGR vs -12.2%).

Epsilon Composite is a French company created in 1987 by Stephane LULL, its current CEO. The company was founded in January 1987. Its production site is located in Gaillan, France. Stéphane Lull is the CEO.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

EPSN vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.3× larger
LAB
$19.6M
$14.8M
EPSN
Growing faster (revenue YoY)
EPSN
EPSN
+77.2% gap
EPSN
65.7%
-11.5%
LAB
Higher net margin
EPSN
EPSN
93.5% more per $
EPSN
-83.9%
-177.4%
LAB
Faster 2-yr revenue CAGR
EPSN
EPSN
Annualised
EPSN
36.2%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
EPSN
EPSN
LAB
LAB
Revenue
$14.8M
$19.6M
Net Profit
$-12.4M
$-34.7M
Gross Margin
48.5%
Operating Margin
-129.0%
-168.5%
Net Margin
-83.9%
-177.4%
Revenue YoY
65.7%
-11.5%
Net Profit YoY
-1535.0%
-28.8%
EPS (diluted)
$-0.55
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EPSN
EPSN
LAB
LAB
Q4 25
$14.8M
Q3 25
$9.0M
$19.6M
Q2 25
$11.6M
$21.8M
Q1 25
$16.2M
$40.8M
Q4 24
$8.9M
Q3 24
$7.3M
$22.1M
Q2 24
$7.3M
$22.5M
Q1 24
$8.0M
$45.5M
Net Profit
EPSN
EPSN
LAB
LAB
Q4 25
$-12.4M
Q3 25
$1.1M
$-34.7M
Q2 25
$1.6M
$-33.5M
Q1 25
$4.0M
$-26.0M
Q4 24
$-760.8K
Q3 24
$366.0K
$-26.9M
Q2 24
$815.7K
$-45.7M
Q1 24
$1.5M
$-32.2M
Gross Margin
EPSN
EPSN
LAB
LAB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
EPSN
EPSN
LAB
LAB
Q4 25
-129.0%
Q3 25
6.7%
-168.5%
Q2 25
7.1%
-118.1%
Q1 25
44.3%
-80.8%
Q4 24
6.8%
Q3 24
3.3%
-120.9%
Q2 24
16.0%
-134.5%
Q1 24
17.6%
-132.2%
Net Margin
EPSN
EPSN
LAB
LAB
Q4 25
-83.9%
Q3 25
11.9%
-177.4%
Q2 25
13.3%
-153.7%
Q1 25
24.8%
-63.8%
Q4 24
-8.5%
Q3 24
5.0%
-122.0%
Q2 24
11.2%
-203.3%
Q1 24
18.9%
-70.6%
EPS (diluted)
EPSN
EPSN
LAB
LAB
Q4 25
$-0.55
Q3 25
$0.05
$-0.09
Q2 25
$0.07
$-0.09
Q1 25
$0.18
$-0.07
Q4 24
$-0.04
Q3 24
$0.02
$-0.07
Q2 24
$0.04
$-0.12
Q1 24
$0.07
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EPSN
EPSN
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$9.0M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$124.7M
$399.7M
Total Assets
$228.2M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EPSN
EPSN
LAB
LAB
Q4 25
$9.0M
Q3 25
$12.8M
$129.4M
Q2 25
$9.9M
$158.6M
Q1 25
$6.9M
$150.9M
Q4 24
$6.5M
Q3 24
$8.3M
$210.6M
Q2 24
$8.6M
$269.8M
Q1 24
$2.3M
$287.1M
Total Debt
EPSN
EPSN
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
EPSN
EPSN
LAB
LAB
Q4 25
$124.7M
Q3 25
$100.2M
$399.7M
Q2 25
$100.2M
$424.5M
Q1 25
$99.7M
$454.6M
Q4 24
$96.7M
Q3 24
$98.4M
$489.3M
Q2 24
$99.6M
$510.3M
Q1 24
$99.9M
$577.3M
Total Assets
EPSN
EPSN
LAB
LAB
Q4 25
$228.2M
Q3 25
$126.3M
$539.6M
Q2 25
$123.6M
$557.0M
Q1 25
$125.5M
$579.6M
Q4 24
$120.5M
Q3 24
$121.8M
$681.5M
Q2 24
$121.1M
$708.7M
Q1 24
$125.1M
$777.7M
Debt / Equity
EPSN
EPSN
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EPSN
EPSN
LAB
LAB
Operating Cash FlowLast quarter
$-277.0K
$-22.2M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EPSN
EPSN
LAB
LAB
Q4 25
$-277.0K
Q3 25
$4.0M
$-22.2M
Q2 25
$8.3M
$-20.7M
Q1 25
$8.6M
$-30.3M
Q4 24
$5.0M
Q3 24
$2.7M
$-27.9M
Q2 24
$5.4M
$-39.0M
Q1 24
$3.7M
$-62.5M
Free Cash Flow
EPSN
EPSN
LAB
LAB
Q4 25
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$-35.3M
Q4 24
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-63.3M
FCF Margin
EPSN
EPSN
LAB
LAB
Q4 25
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
-86.6%
Q4 24
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-138.9%
Capex Intensity
EPSN
EPSN
LAB
LAB
Q4 25
Q3 25
4.5%
Q2 25
8.7%
Q1 25
12.4%
Q4 24
Q3 24
10.2%
Q2 24
8.6%
Q1 24
1.7%
Cash Conversion
EPSN
EPSN
LAB
LAB
Q4 25
Q3 25
3.70×
Q2 25
5.38×
Q1 25
2.14×
Q4 24
Q3 24
7.50×
Q2 24
6.60×
Q1 24
2.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EPSN
EPSN

Gas Oil Ngls And Condensate$13.3M90%
Gas Gathering And Compression$1.5M10%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons